Armis to Protect Cyber-Physical Systems with NVIDIA Cybersecurity AI
12.2.2025 17:00:00 CET | Business Wire | Press release
New integrations of NVIDIA BlueField-3 DPUs and NVIDIA Morpheus enable enhanced visibility and control for IT and OT environments
Armis, the cyber exposure management & security company, today announced that its Armis Centrix™ platform will be enabled by NVIDIA BlueField-3 data processing units (DPUs) and, in the future, the NVIDIA Morpheus cybersecurity AI framework to comprehensively protect critical infrastructure while maintaining operational continuity.
These integrations provide a secure, isolated environment for critical infrastructure sectors without impacting performance or operations. Armis Centrix™, Armis’ cyber exposure management platform, with NVIDIA BlueField-3 DPUs enables customers to safeguard critical OT systems at both the host and network level.
“From the convergence of IT and OT environments to sophisticated cyber threats targeting cyber-physical systems, organizations face growing challenges in securing attack surfaces and managing their cyber risk exposure,” said Nadir Izrael, CTO and Co-Founder at Armis. “This integration with NVIDIA technologies extends the reach of Armis’ comprehensive, best-in-class platform for OT security and cyber exposure management so that more organizations can see, protect and manage their critical assets with operational resiliency.”
Armis Centrix™ deployed on NVIDIA BlueField-3 DPUs fortifies security from the ground to the cloud by leveraging Armis’ AI-powered asset intelligence to detect and mitigate threats in real time. This proactive approach to reducing risk keeps systems functional and secure, preserving business continuity and operational integrity across all asset types.
With its seamless deployment, the integration of Armis’ capabilities into the NVIDIA BlueField-3 DPU platform allows for compatibility and scalability across a wide range of OT environments without compromising performance or resiliency.
“Securing critical infrastructure amid today’s dynamic threat landscape is more important than ever,” said Ofir Arkin, Senior Distinguished Architect for Cybersecurity at NVIDIA. “The NVIDIA cybersecurity AI platform allows innovators like Armis to develop breakthrough technologies for cyber exposure management and security, delivering a powerful, scalable and flexible solution tailored to the needs of modern OT environments.”
Read more about Armis’ integration with the NVIDIA cybersecurity AI platform here.
Armis is showcasing its Armis Centrix™ platform this week at S4x25 in Tampa, Florida. Learn more here and to book a meeting with Armis executives.
About Armis
Armis, the cyber exposure management & security company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212724803/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom